RhumbLine Advisers’s Burning Rock Biotech BNR Stock Holding History

RhumbLine Advisers’s Portfolio BNR Stock Details BNR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-23	Closed	-$72	–	4126
2025 Q2	$72	Sell	23 -6	-21%	-$19	﹤0.01%	4107
2025 Q1	$121	Sell	29 -551	-95%	-$3.44K	﹤0.01%	4096
2024 Q4	$3.91K	Hold	580	–	–	﹤0.01%	3982
2024 Q3	$1.9K	Hold	580	–	–	﹤0.01%	4061
2024 Q2	$3.65K	Sell	580 -1	-0.2%	-$8	﹤0.01%	4129
2024 Q1	$4.23K	Hold	581	–	–	﹤0.01%	4001
2023 Q4	$5.4K	Sell	581 -17	-3%	-$156	﹤0.01%	3968
2023 Q3	$5.8K	Buy	598 +13	+2%	+$203	﹤0.01%	3955
2023 Q2	$12.8K	Buy	+585	New	+$15.5K	﹤0.01%	3892

Other funds holding BNR

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

CRCM LP San Francisco, California $141M AUM 153.09% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SIA

SkyView Investment Advisors Shrewsbury, New Jersey $743M AUM 17.91% 1-Year Est. Return

RhumbLine Advisers's BNR Position: Q3 2025 in Review

RhumbLine Advisers sold out of Burning Rock Biotech (BNR) in Q3 2025, closing a stake of 23 shares — an estimated $72 sold.

RhumbLine Advisers first reported a position in BNR in Q2 2023 and held it in 9 quarters. The position peaked at $12.8K in Q2 2023. 16 funds tracked by Wall St. Rank hold BNR as of Q3 2025.

RhumbLine Advisers reported no remaining Burning Rock Biotech position as of Q3 2025 after selling out during the quarter.
RhumbLine Advisers sold 23 Burning Rock Biotech shares in Q3 2025, an estimated $72.
RhumbLine Advisers first reported a position in Burning Rock Biotech in Q2 2023 and held it in 9 quarters.
RhumbLine Advisers's Burning Rock Biotech position peaked at $12.8K in Q2 2023.
16 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q3 2025.

Based on RhumbLine Advisers's 13F filing for Q3 2025, filed 6 Nov 2025.